Piper Jaffray Downgrades Anthera Pharma (ANTH) to Underweight; PT $0.10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Anthera Pharma (ANTH) PT Lowered to $0.50 at Jefferies
March 12, 2018 11:17 AM EDTJefferies lowered its price target on Anthera Pharma (NASDAQ: ANTH) to $0.50 (from $2.00) while maintaining a Hold rating.
... MoreAnthera Pharma (ANTH) Phase 3 Clinical Study of Sollpura Did Not Meet Primary Endpoint
March 12, 2018 8:01 AM EDTAnthera Pharmaceuticals, Inc. (Nasdaq: ANTH) announced today that Sollpura did not meet the non-inferiority margin of the CFA primary endpoint in the RESULT Phase 3 clinical study of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis.
The design of the RESULT study was based on the outcome of the previous Phase 3 SOLUTION study and included a higher starting dose and more aggressive dose optimizations based on clinical signs and symptoms of malabsorption. In the RESULT... More
